Medline’s Backers Raise $2.1 Billion in Stock Offering, Bloomberg reports
Medline’s Backers Raise $2.1 Billion in Stock Offering, Bloomberg reports.
Medline Inc.
Medline supplies medical-surgical products and supply chain solutions to customers across care settings, including hospitals, surgery centers, physician offices and post-acute facilities. Its two segments are Medline Brand, which offers products in Front Line Care, Surgical Solutions, and Laboratory and Diagnostics, and Supply Chain Solutions, which distributes products from third-party suppliers and provides services such as supply chain consulting, warehouse and technology management, third-party logistics, inventory rationalization, and route planning. As of December 31, 2025, Medline offers approximately 335,000 products across the two segments. Medline makes money by manufacturing and selling its branded products, distributing third-party products, and providing supply chain services. It also enters into multi-year Prime Vendor agreements to serve as customers’ primary distribution partner for most of their medical-surgical needs. Medline distributes through global facilities and its MedTrans truck fleet. Its headquarters are in Northfield, Illinois.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MDLN in the last 30 days.
See all $MDLN insider activity →Medline’s Backers Raise $2.1 Billion in Stock Offering, Bloomberg reports.
Medline Inc. (MDLN) announced a secondary offering of 60M Class A shares at $35.50 each by affiliated stockholders, with a 30-day option for underwriters to buy 9M more. The offering, expected to close Nov. 23, 2026, includes a $200M repurchase by Medline from selling stockholders. Medline is a medical-surgical products provider.
Medline, the world's largest medical-surgical supplier, recalled hospital beds and related products due to 7 deaths and 35 injuries. The recall, announced on Oct. 14, 2026, includes beds, mattresses, and accessories sold between 2011 and 2026. Medline estimates costs of $50M-$200M, with potential legal and reputational risks. The company trades as MDLN on Nasdaq.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning MDLN (Medline Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 6 bearish.
Recent MDLN coverage spans financial news, corporate actions and regulation.
Medline’s Backers Raise $2.1 Billion in Stock Offering, Bloomberg reports.
The large secondary offering may dilute existing shareholders and put downward pressure on MDLN price.
Recall and product-line discontinuation raise near-term liability and regulatory risk, likely pressuring sentiment and earnings expectations.
The large secondary offering will likely dilute existing shareholders and put downward pressure on the stock.
The FDA recalled Medline's medical beds and orthopedic mattresses after seven deaths and 35 injuries due to overheating and design flaws. The recall covers products sold in the US and Canada since 2011. The FDA advised users to disconnect beds and supervise patients.
AlphAI scores every news story that mentions MDLN with an AI model for sentiment and relevance, and aggregates insider trades from Medline Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Medline’s Backers Raise $2.1 Billion in Stock Offering, Bloomberg reports.
Medline Inc. (MDLN) announced a secondary offering of 60M Class A shares at $35.50 each by affiliated stockholders, with a 30-day option for underwriters to buy 9M more. The offering, expected to close Nov. 23, 2026, includes a $200M repurchase by Medline from selling stockholders. Medline is a medical-surgical products provider.
Medline, the world's largest medical-surgical supplier, recalled hospital beds and related products due to 7 deaths and 35 injuries. The recall, announced on Oct. 14, 2026, includes beds, mattresses, and accessories sold between 2011 and 2026. Medline estimates costs of $50M-$200M, with potential legal and reputational risks. The company trades as MDLN on Nasdaq.
Blackstone, Carlyle, and other shareholders are offering 60 million shares of Medline Inc. (MDLN) Class A stock, with a 30-day option for underwriters to buy 9 million more. Medline will not sell shares or receive proceeds. The company plans to repurchase $200 million of shares from sellers. Goldman Sachs, Morgan Stanley, and others are managing the offering.
The FDA recalled Medline's medical beds and orthopedic mattresses after seven deaths and 35 injuries due to overheating and design flaws. The recall covers products sold in the US and Canada since 2011. The FDA advised users to disconnect beds and supervise patients.
UBS kept its Buy rating on Medline and raised its price target to $49 from $43, citing a 23.2% upside from the Nov 5 close. Recent analyst targets range from $44 to $55.
Leerink Partners kept Medline at Outperform, raising its price target to $46 from $43, suggesting 14% upside from the Nov 4 close. Recent analyst targets range from $43 to $55.
Evercore ISI Group kept its Outperform rating on Medline and increased its price target to $44 from $38, suggesting a 9.0% upside from the Nov 4 close of $40.35. Recent analyst price targets for Medline range from $43 to $55.
BTIG retained its Buy rating and $55 price target for Medline, suggesting a 36.3% upside from the Nov 4 close of $40.35. The firm's outlook implies significant potential growth for the company.
Medline, a publicly traded medical supply company, is laying off 304 workers as part of a restructuring effort. The company reported 11% higher net sales but 29% lower net income for the first nine months of the year, citing higher operating expenses and inflation. Medline shares rose about 16% mid-Wednesday.